ENX-104
ENX-104, also known as deuterated nemonapride enantiomer, is a selective dopamine D 2 and D 3 receptor antagonist which is under development for the treatment of major depressive disorder.
≈ 3 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
ENX-104, also known as deuterated nemonapride enantiomer, is a selective dopamine D 2 and D 3 receptor antagonist which is under development for the treatment of major depressive disorder. It is specifically under development for the treatment of major depressive disorder characterized by anhedonia.
The drug is being developed for use at low doses to preferentially block presynaptic dopamine D 2 and D 3 autoreceptors and hence to enhance rather than inhibit dopaminergic neurotransmission. It is taken by mouth.
Pharmacodynamics
ENX-104 is intended for use at low doses to produce preferential presynaptic dopamine D 2 and D 3 autoreceptor antagonism and consequent enhancement of dopaminergic neurotransmission. The target occupancy of the dopamine D 2 and D 3 receptors is approximately 40 to 70%.
For comparison, dopamine D 2 receptor occupancy of 65 to 80% is associated with antipsychotic-like effects and hence with substantial postsynaptic dopamine D 2 receptor antagonism in animals. ENX-104 has been found to increase dopamine and serotonin levels in the nucleus accumbens and prefrontal cortex. It was also found to augment amphetamine-induced dopamine release.
In accordance with these findings, the drug was found to produce anti-anhedonia-like effects, specifically increased reward responsiveness, in animals. Low doses of amisulpride likewise showed anti-anhedonia-like effects.
ENX-104 is not expected to induce motor side effects like extrapyramidal symptoms (EPS) or catalepsy at the low doses employed, as these effects require higher occupancy of the D 2 receptor (e.g., ~80%). ENX-104 is highly potent as a dopamine receptor antagonist.
Its affinities are 0.01 nM for the dopamine D 2L receptor, 0.1 nM for the dopamine D 2S receptor, 0.2 nM for the dopamine D 3 receptor (2- to 20-fold lower than for the D 2 receptor), and 1.6 nM for the dopamine D 4 receptor (8- to 160-fold lower than for the D 2 receptor). The drug is also a weak partial agonist or antagonist of the serotonin 5-HT 2A receptor, with an of 14 nM (70- to 1,400-fold lower than its affinity for the D 2 receptor) and an E max of approximately 40%.
Conversely, ENX-104 showed little or no functional activity at the serotonin 5-HT 1A or 5-HT 7 receptor.
Chemistry
ENX-104 is a benzamide derivative. It is a partially-deuterated analog of the drug nemonapride, which is used to treat schizophrenia.
Clinical trials
As of September 2024, ENX-104 is in phase 1 clinical trials for major depressive disorder. It is under development by Engrail Therapeutics.
See also
List of investigational antidepressants ENX-105 and ENX-205
Text derived from https://en.wikipedia.org/w/index.php?oldid=1338629665 under CC BY-SA 4.0; modifications have been made.